HU9603567D0 - Combination therapy for hiv infection - Google Patents
Combination therapy for hiv infectionInfo
- Publication number
- HU9603567D0 HU9603567D0 HU9603567A HU9603567A HU9603567D0 HU 9603567 D0 HU9603567 D0 HU 9603567D0 HU 9603567 A HU9603567 A HU 9603567A HU 9603567 A HU9603567 A HU 9603567A HU 9603567 D0 HU9603567 D0 HU 9603567D0
- Authority
- HU
- Hungary
- Prior art keywords
- combination therapy
- hiv infection
- hiv
- infection
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26708594A | 1994-06-27 | 1994-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
HU9603567D0 true HU9603567D0 (en) | 1997-02-28 |
HUT76546A HUT76546A (en) | 1997-09-29 |
Family
ID=23017251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9603567A HUT76546A (en) | 1994-06-27 | 1995-06-23 | Combinative pharmaceutical compositions and therapy for treating hiv infection |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0767664A2 (en) |
JP (1) | JPH10503178A (en) |
AU (1) | AU2863895A (en) |
CA (1) | CA2193221A1 (en) |
CZ (1) | CZ375196A3 (en) |
FI (1) | FI965196L (en) |
HU (1) | HUT76546A (en) |
IL (1) | IL114208A0 (en) |
MX (1) | MX9700036A (en) |
NO (1) | NO965591D0 (en) |
PL (1) | PL317876A1 (en) |
SK (1) | SK163996A3 (en) |
WO (1) | WO1996000068A2 (en) |
ZA (1) | ZA955269B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689761B1 (en) | 1995-02-01 | 2004-02-10 | Merck & Co., Inc. | Combination therapy for HIV infection |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
GB2324242A (en) * | 1997-04-18 | 1998-10-21 | Atindra Nath Chakrabarty | Medicaments for treating viral infections |
PL207590B1 (en) | 1999-09-24 | 2011-01-31 | Janssen Pharmaceutica Nv | Antiviral compositions |
EP3353527B1 (en) | 2015-09-23 | 2022-12-28 | Malvern Panalytical Limited | Particle characterisation |
-
1995
- 1995-06-19 IL IL11420895A patent/IL114208A0/en unknown
- 1995-06-23 WO PCT/US1995/007690 patent/WO1996000068A2/en not_active Application Discontinuation
- 1995-06-23 CA CA002193221A patent/CA2193221A1/en not_active Abandoned
- 1995-06-23 CZ CZ963751A patent/CZ375196A3/en unknown
- 1995-06-23 JP JP8503245A patent/JPH10503178A/en active Pending
- 1995-06-23 HU HU9603567A patent/HUT76546A/en unknown
- 1995-06-23 MX MX9700036A patent/MX9700036A/en unknown
- 1995-06-23 SK SK1639-96A patent/SK163996A3/en unknown
- 1995-06-23 PL PL95317876A patent/PL317876A1/en unknown
- 1995-06-23 EP EP95923935A patent/EP0767664A2/en not_active Withdrawn
- 1995-06-23 AU AU28638/95A patent/AU2863895A/en not_active Withdrawn
- 1995-06-26 ZA ZA955269A patent/ZA955269B/en unknown
-
1996
- 1996-12-23 FI FI965196A patent/FI965196L/en not_active Application Discontinuation
- 1996-12-27 NO NO965591A patent/NO965591D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996000068A2 (en) | 1996-01-04 |
SK163996A3 (en) | 1997-08-06 |
JPH10503178A (en) | 1998-03-24 |
FI965196A0 (en) | 1996-12-23 |
IL114208A0 (en) | 1995-10-31 |
NO965591L (en) | 1996-12-27 |
AU2863895A (en) | 1996-01-19 |
CA2193221A1 (en) | 1996-01-04 |
CZ375196A3 (en) | 1997-07-16 |
WO1996000068A3 (en) | 1996-02-22 |
EP0767664A2 (en) | 1997-04-16 |
PL317876A1 (en) | 1997-04-28 |
HUT76546A (en) | 1997-09-29 |
FI965196L (en) | 1996-12-23 |
MX9700036A (en) | 1997-04-30 |
NO965591D0 (en) | 1996-12-27 |
ZA955269B (en) | 1996-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0707855A3 (en) | Combination therapy for chronic hepatitis C infection | |
IL115310A0 (en) | Combination therapy for hypercholesterolemia | |
AP9700951A0 (en) | Medicaments | |
GB9411080D0 (en) | Treatment | |
AU7973994A (en) | Combination therapy for hiv infection | |
GB9406573D0 (en) | Medicaments | |
ZA9533B (en) | Pentolifylline therapy | |
HRP960045B1 (en) | Combination therapy for hiv infection | |
HU9603567D0 (en) | Combination therapy for hiv infection | |
IL114415A0 (en) | Anti-HIV triple therapeutic combination | |
ZA953237B (en) | Medical treatment | |
GB9411052D0 (en) | Medicaments | |
ZA956662B (en) | Combination therapy for HIV infection | |
AU1925295A (en) | Ribozyme therapy for hepatitis b infection | |
EP0724882A4 (en) | Novel anti-hiv drug | |
EP0790829A4 (en) | Medicaments | |
GB9408693D0 (en) | Medicament | |
GB9419954D0 (en) | Medicament | |
GB9420703D0 (en) | Medicament | |
GB9400159D0 (en) | Medicament solution | |
GB9418077D0 (en) | Medical aid | |
GB9701117D0 (en) | HIV Treatment | |
GB9708380D0 (en) | HIV treatment | |
GB9420340D0 (en) | Therapeutic improvement | |
GB9404379D0 (en) | Therapeutic improvement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFD9 | Temporary protection cancelled due to non-payment of fee |